{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:11:36Z","timestamp":1773936696855,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04713-9","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:05:59Z","timestamp":1772705159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of GP73 in predicting overall survival and chemotherapy response in locally advanced gastric cancer: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2024-7751","authenticated-orcid":false,"given":"Altay","family":"Aliyev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5527-4434","authenticated-orcid":false,"given":"Arturan","family":"Ibrahimli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3341-6462","authenticated-orcid":false,"given":"Johnn Henry Herrera","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0540-5667","authenticated-orcid":false,"given":"Elgun","family":"Samadov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2496-1941","authenticated-orcid":false,"given":"Farida","family":"Aghayarli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8400-1867","authenticated-orcid":false,"given":"Iqbal","family":"Babazade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6958-0051","authenticated-orcid":false,"given":"Parvana","family":"Asgarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-930X","authenticated-orcid":false,"given":"Adila","family":"Adilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4534-7722","authenticated-orcid":false,"given":"Akbar","family":"Hajiyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-6990","authenticated-orcid":false,"given":"Jamal","family":"Musayev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"4713_CR1","doi-asserted-by":"publisher","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pi\u00f1eros M, Znaor A, Parkin DM, Soerjomataram I, Bray F. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer. 2024. https:\/\/doi.org\/10.1002\/ijc.35278. Epub ahead of print. PMID:39688499.","DOI":"10.1002\/ijc.35278"},{"issue":"1","key":"4713_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.suc.2024.06.006","volume":"105","author":"J Liu-Burdowski","year":"2025","unstructured":"Liu-Burdowski J, Park J. Treatment of early gastric cancer. Surg Clin North Am. 2025;105(1):55\u201363. https:\/\/doi.org\/10.1016\/j.suc.2024.06.006. Epub 2024 Aug 1. PMID:39523076.","journal-title":"Surg Clin North Am"},{"issue":"9813","key":"4713_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(11)61873-4. Epub 2012 Jan 7. PMID:22226517.","journal-title":"Lancet"},{"issue":"3","key":"4713_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","volume":"18","author":"D Cunningham","year":"2017","unstructured":"Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK MRC ST03): primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial. Lancet Oncol. 2017;18(3):357\u201370. Epub 2017 Feb 3. PMID:28163000. PMCID:PMC5337626.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4713_CR5","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.21873\/anticanres.17320","volume":"44","author":"T Oshima","year":"2024","unstructured":"Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, et al. Biomarker study for selecting neoadjuvant chemotherapy regimens based on prognostic prediction using gastric cancer biopsy specimens from a phase II randomized controlled trial. Anticancer Res. 2024;44(11):4951\u201360. https:\/\/doi.org\/10.21873\/anticanres.17320. PMID:39477312.","journal-title":"Anticancer Res"},{"issue":"19","key":"4713_CR6","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, et al. Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med. 2024;391(19):1810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2405195. Epub 2024 Sep 14. PMID:39282905.","journal-title":"N Engl J Med"},{"issue":"10184","key":"4713_CR7","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID:30982686.","journal-title":"Lancet"},{"key":"4713_CR8","doi-asserted-by":"publisher","unstructured":"Rencuzogullari A, Karahan SN, Selcukbiricik F, Lacin S, Taskin OC, Saka B, et al. The new era of total neoadjuvant FLOT therapy for locally advanced resectable gastric cancer: a propensity-matched comparison with standard perioperative therapy. J Surg Oncol. 2024. https:\/\/doi.org\/10.1002\/jso.27934. Epub ahead of print. PMID:39400342.","DOI":"10.1002\/jso.27934"},{"issue":"1\u20132","key":"4713_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0378-1119(00)00136-0","volume":"249","author":"RD Kladney","year":"2000","unstructured":"Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene. 2000;249(1\u20132):53\u201365. https:\/\/doi.org\/10.1016\/S0378-1119(00)00136-0. PMID:10831838. PMCID:PMC7127640.","journal-title":"Gene"},{"issue":"1","key":"4713_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12876-023-03050-5","volume":"23","author":"WM Yu","year":"2023","unstructured":"Yu WM, Li GW, Lou MG, Wu ZY. Prognostic impact of tissue Golgi protein 73 in hepatocellular carcinoma: a meta-analysis. BMC Gastroenterol. 2023;23(1):401. https:\/\/doi.org\/10.1186\/s12876-023-03050-5. PMID:37978447. PMCID:PMC10656938.","journal-title":"BMC Gastroenterol"},{"key":"4713_CR11","doi-asserted-by":"publisher","first-page":"7417","DOI":"10.2147\/OTT.S181239","volume":"11","author":"R Liang","year":"2018","unstructured":"Liang R, Liu Z, Piao X, Zuo M, Zhang J, Liu Z, et al. Research progress on GP73 in malignant tumors. Onco Targets Ther. 2018;11:7417\u201321. PMID:30425529. PMCID:PMC6204869.","journal-title":"Onco Targets Ther"},{"issue":"8","key":"4713_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/imcb.12664","volume":"101","author":"MT Frans","year":"2023","unstructured":"Frans MT, Kuipers EM, Bianchi F, van den Bogaart G. Unveiling the impact of GOLM1\/GP73 on cytokine production in cancer and infectious disease. Immunol Cell Biol. 2023;101(8):727\u201334. https:\/\/doi.org\/10.1111\/imcb.12664. Epub 2023 Jun 18. PMID:37332154.","journal-title":"Immunol Cell Biol"},{"key":"4713_CR13","doi-asserted-by":"publisher","first-page":"0425","DOI":"10.34133\/research.0425","volume":"7","author":"Y Liu","year":"2024","unstructured":"Liu Y, Hu X, Zhou S, Sun T, Shen F, Zeng L. Golgi protein 73 promotes angiogenesis in hepatocellular carcinoma. Res (Wash D C). 2024;7:0425. https:\/\/doi.org\/10.34133\/research.0425. PMID:39022745. PMCID:PMC11251733.","journal-title":"Res (Wash D C)"},{"issue":"5","key":"4713_CR14","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.3892\/or.2014.3404","volume":"32","author":"G Liu","year":"2014","unstructured":"Liu G, Zhang Y, He F, Li J, Wei X, Li Y, et al. Expression of GOLPH2 is associated with progression and poor prognosis in gastric cancer. Oncol Rep. 2014;32(5):2077\u201385. https:\/\/doi.org\/10.3892\/or.2014.3404. Epub 2014 Aug 14. PMID:25119897.","journal-title":"Oncol Rep"},{"key":"4713_CR15","doi-asserted-by":"publisher","first-page":"603838","DOI":"10.3389\/pore.2021.603838","volume":"27","author":"JG Shen","year":"2021","unstructured":"Shen JG, Shen J, Teng RY, Wang LB, Zhao WH, Wang QC. High GP73 expression correlates with poor response to neoadjuvant chemotherapy and survival in gastric cancer: a tissue microarray study. Pathol Oncol Res. 2021;27:603838. https:\/\/doi.org\/10.3389\/pore.2021.603838. PMID:34257562. PMCID:PMC8262201.","journal-title":"Pathol Oncol Res"},{"key":"4713_CR16","doi-asserted-by":"publisher","unstructured":"Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19940601)73:11%3C;2680::aid-cncr2820731105%3E;3.0.co;2-c. PMID:8194005.","DOI":"10.1002\/1097-0142(19940601)73:11%3C;2680::aid-cncr2820731105%3E;3.0.co;2-c"},{"issue":"7","key":"4713_CR17","doi-asserted-by":"publisher","first-page":"e70191","DOI":"10.1371\/journal.pone.0070191","volume":"8","author":"Q Wang","year":"2013","unstructured":"Wang Q, Liu X, Zhou J, Huang Y, Zhang S, Shen J, et al. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PLoS ONE. 2013;8(7):e70191. https:\/\/doi.org\/10.1371\/journal.pone.0070191. PMID:23922955. PMCID:PMC3726373.","journal-title":"PLoS ONE"},{"key":"4713_CR18","doi-asserted-by":"publisher","first-page":"119999","DOI":"10.1016\/j.cca.2024.119999","volume":"565","author":"\u0141 Szternel","year":"2025","unstructured":"Szternel \u0141, Sobucki B, Wieprzycka L, Krintus M, Panteghini M. Golgi protein 73 in liver fibrosis. Clin Chim Acta. 2025;565:119999. https:\/\/doi.org\/10.1016\/j.cca.2024.119999. Epub 2024 Oct 12. PMID:39401651.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"4713_CR19","first-page":"551","volume":"8","author":"LM Aruna, Li","year":"2018","unstructured":"Aruna, Li LM. Overexpression of Golgi membrane protein 1 promotes non-small-cell carcinoma aggressiveness by regulating matrix metallopeptidase 13. Am J Cancer Res. 2018;8(3):551\u201365. PMID:29637008. PMCID:PMC5883103.","journal-title":"Am J Cancer Res"},{"issue":"10","key":"4713_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41389-021-00358-3","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang J, Yang R, Cheng Y, Zhou Y, Li H, et al. GP73-mediated secretion of AFP and GP73 promotes proliferation and metastasis of hepatocellular carcinoma cells. Oncogenesis. 2021;10(10):69. https:\/\/doi.org\/10.1038\/s41389-021-00358-3. PMID:34650031. PMCID:PMC8516944.","journal-title":"Oncogenesis"},{"issue":"1","key":"4713_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41419-025-07391-9","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Zhang T, Zhou Y, Jiao Z, Lu K, Liu X, et al. GP73-mediated secretion of PKM2 and GP73 promotes angiogenesis and M2-like macrophage polarization in hepatocellular carcinoma. Cell Death Dis. 2025;16(1):69. https:\/\/doi.org\/10.1038\/s41419-025-07391-9. PMID:39904999. PMCID:PMC11794714.","journal-title":"Cell Death Dis"},{"issue":"4","key":"4713_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.livres.2020.09.003","volume":"4","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wan YY. Golgi protein 73, hepatocellular carcinoma and other types of cancers. Liver Res. 2020;4(4):161\u20137. https:\/\/doi.org\/10.1016\/j.livres.2020.09.003. Epub 2020 Sep 25. PMID:33343966. PMCID:PMC7743997.","journal-title":"Liver Res"},{"issue":"11","key":"4713_CR23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1001\/jamaoncol.2024.4085","volume":"10","author":"CL Chiang","year":"2024","unstructured":"Chiang CL, Chan KSK, Chiu KWH, Lee FAS, Chen W, Wong NSM, et al. Complete response to locoregional therapy plus immunotherapy for hepatocellular carcinoma. JAMA Oncol. 2024;10(11):1548\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2024.4085. PMID:39325464. PMCID:PMC11428022.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4713_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12094-017-1707-1","volume":"20","author":"ML S\u00e1nchez de Molina","year":"2018","unstructured":"S\u00e1nchez de Molina ML, D\u00edaz del Arco C, Vorwald P, Garc\u00eda-Olmo D, Estrada L, Fern\u00e1ndez-Ace\u00f1ero MJ. Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma. Clin Transl Oncol. 2018;20(2):253\u20137. https:\/\/doi.org\/10.1007\/s12094-017-1707-1. Epub 2017 Jun 26. PMID:28653276.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"4713_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/DCR.0000000000003395","volume":"68","author":"S Yilmaz","year":"2025","unstructured":"Yilmaz S, Liska D, Conces ML, Tursun N, Elamin D, Ozgur I, et al. Predictors of complete response to total neoadjuvant therapy in locally advanced rectal cancer. Dis Colon Rectum. 2025;68(1):60\u20138. https:\/\/doi.org\/10.1097\/DCR.0000000000003395. Epub 2024 Sep 11. PMID:39260428.","journal-title":"Dis Colon Rectum"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04713-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:22:15Z","timestamp":1773930135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04713-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4713"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04713-9","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of the Liv Bona Dea Hospital (2024-1103). Patient consent was waived owing to the retrospective data selection. This was approved by the ethics committee of the Liv Bona Dea Hospital (2024-1103).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Anonymized data were used in this study. Therefore, participant consent to publish was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}